Literature DB >> 16027917

Enantioselective total synthesis of bioactive natural product (+)-Sch 642305: a structurally novel inhibitor of bacterial DNA primase and HIV-1 Tat transactivation.

Goverdhan Mehta1, Harish M Shinde.   

Abstract

The total synthesis of the bioactive natural product (+)-Sch 642305 has been achieved from a readily available chiral building block using an RCM protocol to construct the key decalactone moiety; our approach is notable for its built-in flexibility and is diversity oriented.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16027917     DOI： 10.1039/b505264e

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  5 in total

1.  Quasi-Biomimetic Ring Contraction Catalyzed by a Cysteine-Based Nucleophile: Total Synthesis of Sch-642305, Some Analogs and their Putative anti-HIV Activities.

Authors:  Alpay Dermenci; Philipp S Selig; Robert A Domaoal; Krasimir A Spasov; Karen S Anderson; Scott J Miller
Journal:  Chem Sci       Date:  2011-08-01       Impact factor: 9.825

2.  A practical, convergent route to the key precursor to the tetracycline antibiotics.

Authors:  David A Kummer; Derun Li; Amelie Dion; Andrew G Myers
Journal:  Chem Sci       Date:  2011-09       Impact factor: 9.825

3.  Synthesis of (+)-sch 642305 by a biomimetic transannular Michael reaction.

Authors:  Barry B Snider; Jingye Zhou
Journal:  Org Lett       Date:  2006-03-30       Impact factor: 6.005

Review 4.  Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target.

Authors:  Andrew Robinson; Rebecca J Causer; Nicholas E Dixon
Journal:  Curr Drug Targets       Date:  2012-03       Impact factor: 3.465

5.  Investigating the biosynthesis of Sch-642305 in the fungus Phomopsis sp. CMU-LMA.

Authors:  Francesco Trenti; Karen E Lebe; Emilie Adelin; Jamal Ouazzani; Carsten Schotte; Russell J Cox
Journal:  RSC Adv       Date:  2020-07-21       Impact factor: 4.036
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.